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ABSTRACT 
 
 Cannabis use has been associated with psychosis and cognitive dysfunction. Some evidence 
suggests that the acute behavioral and neurocognitive effects of the main active ingredient in 
cannabis, (−)-trans-Δ9-tetrahydrocannabinol (∆9-THC), might be modulated by previous cannabis 
exposure. However, this has not been investigated either using a control group of non-users, or 
following abstinence in modest cannabis users, who represent the majority of recreational users. 
Twenty-four healthy men participated in a double-blind, randomized, placebo-controlled, repeated-
measures, within-subject, ∆9-THC challenge study. Compared to non-users (N=12; <5 lifetime 
cannabis joints smoked), abstinent modest cannabis users (N=12; 24.5±9 lifetime cannabis joints 
smoked) showed worse performance and stronger right hemispheric activation during cognitive 
processing, independent of the acute challenge (all P≤0.047). Acute ∆9-THC administration 
produced transient anxiety and psychotomimetic symptoms (all P≤0.02), the latter being greater in 
non-users compared to users (P=0.040). Non-users under placebo (control group) activated specific 
brain areas to perform the tasks, while deactivating others. An opposite pattern was found under 
acute (∆9-THC challenge in non-users) as well as residual (cannabis users under placebo) effect of 
∆9-THC. Under ∆9-THC, cannabis users showed brain activity patterns intermediate between those 
in non-users under placebo (control group), and non-users under ∆9-THC (acute effect) and 
cannabis users under placebo (residual effect). In non-users, the more severe the ∆9-THC-induced 
psychotomimetic symptoms and cognitive impairments, the more pronounced was the 
neurophysiological alteration (all P≤0.036). Previous modest cannabis use blunts the acute 
behavioral and neurophysiological effects of ∆9-THC, which are more marked in people who have 
never used cannabis. 
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INTRODUCTION 
   
 Cannabis is widely used, with approximately 200 million users worldwide (National 
Academies of Sciences, 2017). Both cannabis (Henquet et al., 2005; Skinner et al., 2011; van Gastel 
et al., 2012; Colizzi and Murray, 2018) and its key psychoactive ingredient delta-9-
tetrahydrocannabinol (∆9-THC) (Bhattacharyya et al., 2012a; Bhattacharyya et al., 2009; D'Souza 
et al., 2004) can induce psychotic symptoms and trigger the onset of psychosis in vulnerable 
individuals (Colizzi et al., 2015a; Colizzi et al., 2015b; Moore et al., 2007; Morrison et al., 2015). 
Moreover, cannabis use can exacerbate psychotic symptoms (Ouellet-Plamondon et al., 2017; 
Schoeler et al., 2016a; Seddon et al., 2016), increase risk of non-remission (Colizzi et al., 2016a) 
and cause relapse (Patel et al., 2016; Schoeler et al., 2016b) in patients with established psychosis in 
a dose-dependent manner (Schoeler et al., 2016c).  
 Cannabis use has also been associated with cognitive impairments in similar domains to 
those where impairments are seen in patients with schizophrenia, such as memory and attention 
(Ganzer et al., 2016; Solowij and Michie, 2007). However, there is inconsistency with regard to the 
precise nature and extent of the effects of cannabis on human cognition (Bolla et al., 2002; Jockers-
Scherubl et al., 2007; Pope et al., 2001; Solowij et al., 2002; Colizzi and Bhattacharyya, 2017). 
Long-lasting detrimental effects of cannabis use on cognition are still debated and appear to be 
more prominent on specific cognitive domains, such as verbal and visual memory, as suggested by 
meta-analytic evidence (Grant et al., 2003; Schoeler et al., 2016d). Results from experimental 
studies investigating the acute neurocognitive effects of ∆9-THC are more consistent and suggest 
that ∆9-THC administration in healthy volunteers acutely impairs several cognitive domains, 
including verbal (Curran et al., 2002; D'Souza et al., 2004; Ranganathan and D'Souza, 2006) and 
working memory (D'Souza et al., 2004; Ranganathan and D'Souza, 2006) and inhibitory control 
(McDonald et al., 2003; Ramaekers et al., 2009; Ramaekers et al., 2006; Weinstein et al., 2008a) 
processing. Additional evidence from neuroimaging studies suggests that acute ∆9-THC 
 
 
administration disrupts the neurophysiological underpinnings of a variety of cognitive processes 
that are also impaired in patients with psychosis, including verbal memory (Bhattacharyya et al., 
2012a; Bhattacharyya et al., 2009), inhibitory control processing (Bhattacharyya et al., 2015a; 
Hester et al., 2009; Weinstein et al., 2008b), emotional processing and attentive salience 
(Bhattacharyya et al., 2012b; Bhattacharyya et al., 2015b; Bhattacharyya et al., 2010), and visual 
and auditory processing (Bhattacharyya et al., 2010; Winton-Brown et al., 2011).  
 Previous cannabis exposure has been associated with less marked effects of acute ∆9-THC 
administration on cognitive functioning (memory) as well as behavioral measures (observed and 
experienced psychiatric symptoms) and electrophysiological (gamma (γ)-band oscillations and 
P300 wave), neurochemical ((brain-derived neurotrophic factor (BDNF)), and neuroendocrine 
markers (cortisol) (Cortes-Briones et al., 2015; D'Souza et al., 2008a; D'Souza et al., 2008b; 
D'Souza et al., 2012; Ramaekers et al., 2009; Ranganathan et al., 2009; Schoeler and 
Bhattacharyya, 2013). While this may suggest a development of tolerance to the effects of ∆9-THC 
in cannabis users (Gonzalez et al., 2005; Hirvonen et al., 2012; Jones et al., 1981), the interpretation 
of these findings is challenging in light of methodological heterogeneity between the studies in 
terms of pattern of cannabis use and abstinence period prior to assessment. Some studies conducted 
exploratory analyses of the association between recent exposure to cannabis (in 30 days before 
study participation) and electrophysiological measures within a single group of subjects with a wide 
variation in the extent of previous cannabis exposure in terms of lifetime use (from <5 to >1000 
times lifetime), frequency of use during periods of heaviest use (from ≤1 per year to daily), and in 
recent times (from 0 to 29 days in the last month) (Cortes-Briones et al., 2015; D'Souza et al., 
2012). On the other hand, a study that compared 2 separate groups did not include a control group 
of non-users, comparing heavy (on average, 340 occasions in the last year and 6.2 years of history 
of exposure) and occasional cannabis users (on average, 55 occasions in the last year and 7.4 years 
of history of exposure) with no abstinent period prior to assessment (Ramaekers et al., 2009). Other 
studies compared frequent users (≥ 100 times lifetime) with a history of sustained and/ or daily use 
 
 
and with no or modest (≥ 72 h to < 1 month) abstinence period prior to assessment, and controls 
with a wide range of previous cannabis exposure in terms of frequency (< 5 to > 100 times lifetime) 
and either a relatively short (< 1 month) or a heterogeneous abstinence period (> 1week and < 10 
years) (D'Souza et al., 2008a; D'Souza et al., 2008b; Ranganathan et al., 2009). Hence, whether 
modest previous exposure to cannabis, that reflects the typical pattern of use of the majority of 
recreational cannabis users (National Academies of Sciences, 2017), affect the acute cognitive and 
psychotomimetic effects of its key psychoactive ingredient (∆9-THC) as well as the 
neurophysiological effects that may underlie these behavioural effects, remains unclear.  
We sought to address this issue by systematically investigating how the acute behavioural and 
neurophysiological effects (as indexed using functional magnetic resonance imaging; fMRI) of Δ9-
THC differ between non-users and abstinent cannabis users with modest previous cannabis 
exposure who have a negative result on urine drug screen.  
 Employing a placebo-controlled acute pharmacological challenge design in conjunction with 
fMRI, we examined the following hypotheses: 1) modest cannabis use would be associated with 
residual symptomatic, cognitive, and underlying neurophysiological effects measured using fMRI 
blood oxygen level-dependent haemodynamic response (BOLD) signal; 2) acute ∆9-THC effects on 
symptomatic, cognitive, and neurophysiological signals that underpin its effects on key cognitive 
processes affected by cannabis use would be more marked in non-users than users.         
 
 
 
 
 
 
 
 
 
 
EXPERIMENTAL PROCEDURES  
 
 Data presented here are based on that acquired during a previous experimental study, the 
methods of which have already been reported in detail (Bhattacharyya et al., 2015a; Bhattacharyya 
et al., 2009). In brief, this study employed a double-blind, randomized, placebo-controlled, 
repeated-measures, within-subject design, with counterbalanced order of drug administration (Δ9-
THC, placebo), using an established protocol (Bhattacharyya et al., 2012a; Bhattacharyya et al., 
2010). Randomization was performed using a Random Number Generator freely available online 
with blocks of size 6. The two study sessions were separated by at least one-month interval. 
Following drug administration, study participants were imaged using fMRI (1.5 Tesla scanner).  
 In the present manuscript, we focus on the effects of previous cannabis exposure on the 
acute effects of Δ9-THC, which have not been reported before. 
 
Study protocol 
 
 Two hours before each session, study participants had a light standardized breakfast after an 
overnight fast. Also, participants were advised to get at least 6 hours sleep the night before each 
session. One hour before imaging, they were given a gelatin capsule containing Δ9-THC (10 mg, 
approximately 99.6% pure; THC-Pharm, Frankfurt, Germany), or flour (placebo). A dose of 10 mg 
of Δ9-THC was used, as previous work has suggested that this dose can induce detectable effects on 
cognitive processes without causing marked psychotic or anxiety reactions that may affect the 
ability of participants to complete the imaging component of the study (Chesher et al., 1990; Koethe 
et al., 2006; Leweke et al., 1999). Some previous studies have used even higher doses of Δ9-THC 
(≥ 15 mg), however these investigations aimed at assessing the effects of Δ9-THC administration in 
individuals with cannabis dependence (Fischer et al., 2014) or the deposition of cannabinoids in 
human hair following controlled administration of Δ9-THC (Huestis et al., 2007). All subjects had a 
 
 
negative urinary drug screen for amphetamines, benzodiazepines, cocaine, opiates, and Δ9-THC, 
tested before each session using immunometric assay kits. They were asked to refrain from smoking 
for 4 hours, to take caffeine for 12 hours and alcohol for 24 hours prior to each scan session. Also, 
subjects were advised to abstain from using any substance throughout the duration of the study. 
 
Subjects 
 
 Thirty-six healthy, English-speaking, right-handed males participated in this study. 
Participants were recruited using local advertisements and a list of healthy participants who had 
agreed to be contacted for research studies. All except 3 (1 Chinese and 2 Sri-Lankan) of the 
volunteers were white Europeans. Demographic information such as age (Mean ± SD; age: 26.0 ± 
5.6 years) and level of education (17.1 ± 4.2 years) was recorded and Intelligence Quotient (IQ, 
97.7 ± 6.0) was also measured using the National Adult Reading Test (Schlosser and Ivison, 1989) 
(NART). All subjects gave written, informed consent, and completed all of the components of the 
study. Personal or family history of psychiatric illness in first-degree relatives represented an 
exclusion criterion in addition to the standard MRI exclusion criteria. None of the subjects included 
in the study had used more than 21 units/week of alcohol on a regular basis (1 unit = 8 grams of 
pure alcohol). Nine subjects had lifetime history of smoking cigarettes, two of them smoked > 10 
cigarettes/ day, and only one subject smoked at that level at the time of the study (number of 
cigarettes smoked/day; M ± SD, 1.2 ± 3.2; Range: 0-15). 
 
Lifetime cannabis and other substance use  
 
 Cannabis as well as other substance use was assessed using the Structured Clinical Interview 
for DSM Disorders (SCID) and the Addiction Severity Index (McLellan et al., 1992). Lifetime 
cannabis exposure was indexed as the total number of cannabis joints used in their lifetime at the 
 
 
time of taking part in the study. In accordance with the World Health Organization (WHO) 
standards (Haro et al., 2006) lifetime cannabis use less than 5 times was considered negligible use 
and subjects reporting negligible use were categorised as non-users (NU). Out of the total cohort of 
36 subjects, 12 subjects qualified as NU, representing the lower tertile of the sample in terms of 
lifetime cannabis use. When testing for the effects of Δ9-THC on symptoms, cognition, and brain 
function as a function of lifetime cannabis use, this lower tertile (NU; cannabis joints smoked: 3.5 ± 
1, range: 2-5; age: 25.3 ± 4.1 years; level of education: 16.0 ± 3.5 years; IQ, 97.5 ± 7.1; tobacco 
users: 4 subjects) of the sample was compared with the upper tertile of the sample in terms of 
lifetime cannabis use (cannabis users, CU; cannabis joints smoked: 24.5 ± 9; range: 14-40; age: 
27.2 ± 6.9 years; level of education: 19.0 ± 5.7 years; IQ, 98.2 ± 7.9; tobacco users: 3 subjects), for 
a more differentiated analysis (N = 24). This pattern of lifetime cannabis use is comparable with 
that of recreational cannabis users (≥ 10 times) who have participated in previous investigations of 
the acute effects of Δ9-THC on behavioral measures (McDonald et al., 2003). This approach of 
splitting the total sample into upper and lower tertiles in terms of lifetime cannabis use was adopted 
to ensure that the two groups (CU and NU) were sufficiently different in terms of previous cannabis 
exposure such that the modulatory effects of modest previous exposure on acute effects may be 
investigated. Subjects were asked not to have used cannabis in the 3 months before the first scan. 
We did not include individuals with heavier patterns of cannabis use in order to avoid the 
confounding effects of withdrawal symptoms which have been reported following the cessation of 
heavy cannabis use (Budney et al., 2003). Hereafter, unless otherwise specified, subjects will refer 
to only these 24 participants. However, for the sake of completeness, the acute behavioral and 
symptomatic effects of Δ9-THC on the entire sample (N = 36) are also reported. 
 The same WHO criterion (Haro et al., 2006) adopted for cannabis use was used to screen for 
other substance use in terms of exclusion criterion. None of the subjects included in this study had 
used any other substance more than 5 times in their life.  
 
 
 
Whole-blood Δ9-THC levels and physiological measures 
 
 Blood samples were obtained from an indwelling intravenous line in the nondominant arm 
immediately before and at 1, 2, and 3 hours after drug administration. Whole-blood drug levels 
were measured using commercially available agents (Tricho-Tech, Cardiff, England). Heart rate 
and blood pressure were monitored via a digital recorder and an automated arm cuff. 
 
Psychopathological measures 
 
 Immediately before and at 1, 2, and 3 hours after drug administration, psychopathological 
ratings were recorded by an expert clinical researcher using the Positive and Negative Syndrome 
Scale (Kay et al., 1987) (PANSS) and the State-Trait Anxiety Inventory (Guillen-Riquelme and 
Buela-Casal, 2014) (STAI), in order to assess psychotic and anxiety symptoms. As measures of 
sedation and intoxication, the Visual Analog Mood Scale (Folstein and Luria, 1973) (VAMS), and 
Analog Intoxication Scale (Mathew et al., 1992) (AIS) were also administered. For the symptomatic 
effects of Δ9-THC, the area under the curve (AUC) of effects versus time was first calculated by the 
trapezoidal rule and was contrasted with the placebo condition.  
 
Cognitive and imaging paradigms 
 
 Based on the consistent and replicated evidence that cannabis exposure might affect verbal 
memory and learning (Grant et al., 2003; Schoeler and Bhattacharyya, 2013), as well as inhibitory 
control processing (Bhattacharyya et al., 2015a; McDonald et al., 2003; Ramaekers et al., 2006; 
Tapert et al., 2007), during each imaging session participants performed: 1. a verbal paired 
associate learning task comprising 3 conditions (‘encoding’, ‘recall’, and ‘baseline’), with stimuli 
presented visually in blocks (Schlosser and Ivison, 1989; Warner et al., 1987); 2. a response 
 
 
inhibition task, requiring either the execution (‘Go’) or the inhibition (‘No-Go’) of a motor response 
depending on the visual presentation of stimuli (Borgwardt et al., 2008). fMRI data was analysed 
using a non-parametric factorial analysis of variance (XBAM version 4.1), in order to test for the 
main effects as well as the interaction of lifetime cannabis exposure and drug administration on 
brain function, contrasting whole-brain activation while performing the tasks in CU with that 
obtained from NU. Further description of the cognitive tasks along with details about the imaging 
data acquisition and analysis is reported in Supplementary methods.  
 
Ethics 
 
 The study was approved by the Joint South London and Maudsley (SLaM) and Institute of 
Psychiatry, Psychology & Neuroscience (IoPPN) National Health Service Research Ethics 
Committee, and the investigators had a license to use Δ9-THC for research purposes. The authors 
assert that all procedures contributing to this work comply with the ethical standards of the relevant 
national and institutional committees on human experimentation and with the Helsinki Declaration 
of 1975, as revised in 2008. 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
 There were no significant differences between the CU (N = 12) and NU (N = 12) groups in 
terms of demographic variables, proportion of tobacco users, Δ9-THC blood levels, and 
physiological measures (all P > 0.1; Supplementary results). 
 
Psychopathological measures 
 
Acute effect of Δ9-THC 
 As expected, administration of Δ9-THC was associated with the acute induction of 
psychotic symptoms (area under the curve, AUC, PANSS positive symptoms subscale, t = 3.76, P = 
0.01; AUC PANSS negative symptoms subscale, t = 2.87, P = 0.009; AUC PANSS general 
symptoms subscale, t = 4.27, P < 0.001; AUC PANSS total score, t = 4.30, P < 0.001) in the present 
study sample as in the total cohort (Supplementary results). Δ9-THC also induced a significant 
acute increase in anxiety (AUC STAI scale, t = 2.51, P = 0.02) and intoxication (AUC AIS, t = 
5.85, P < 0.001) and a trend-level increase in mental (AUC VAMS mental sedation subscale, t = 
1.89, P = 0.07) but not physical sedation (AUC VAMS physical sedation subscale, P > 0.1).  
 
Acute effect of Δ9-THC clustered by lifetime cannabis exposure 
 Under placebo, CU and NU did not differ in psychopathological ratings (P > 0.1). However, 
as hypothesized, the effect of Δ9-THC on psychotic symptoms was more pronounced in NU 
compared to CU, with a significantly higher AUC PANSS total score (F = 4.77, P = 0.040; Figure 
1) and a trend towards significance for all of the AUC PANSS subscales (NU > CU; AUC PANSS 
positive symptoms subscale; F = 3.91, P = 0.061; AUC PANSS negative symptoms subscale; F = 
4.08, P = 0.056; AUC PANSS general symptoms subscale; F = 4.11, P = 0.055). There was no 
significant (P > 0.1) difference in Δ9-THC-induced symptoms of anxiety or sedation between CU 
 
 
and NU. In addition, there was no significant effect of order of drug administration and no 
interaction between the effects of drug and order of administration on any of the psychopathological 
measures. 
 
Behavioral measures 
 
Verbal paired associate learning task performance  
 As in the total cohort (Supplementary results), there was no significant effect of Δ9-THC on 
performance during the learning task as measured by recall score (P > 0.1) in the combined CU and 
NU sample. However, there was progressive improvement in word recall with repeated presentation 
of word pairs across encoding blocks for both drug conditions (F = 8.21, P < 0.001), with no 
significant effect of Δ9-THC on this repetition-related improvement (P > 0.1). Compared to NU, 
during the placebo condition CU showed slower learning as indexed by slower improvement in 
recall score across repeated blocks (F = 4.17, P = 0.047). This effect was no longer significant 
during the Δ9-THC condition. There was also no significant effect of order of drug administration 
and no interaction between the effects of drug and order of administration on recall score. 
 
Response inhibition (Go/No-Go) task performance 
 There was a higher frequency of inhibition errors under Δ9-THC (6.4%) than under placebo 
(1.9%; χ2 = 14.7; P < 0.001) in the current study sample similar to the total cohort (Supplementary 
results). However, while NU made significantly more errors under the influence of Δ9-THC 
compared to placebo (Δ9-THC: 6.25%, placebo: 0.35%; P < 0.001), in CU the Δ9-THC-induced 
increase in frequency of inhibition errors was less pronounced (Δ9-THC: 6.6%, placebo: 3.5%; χ2 = 
2.94; P = 0.09). Compared to NU, during the placebo condition CU reported ten times more 
inhibition errors (P = 0.01). This effect was no longer significant during the Δ9-THC condition, 
with a similar pattern in terms of frequency of inhibition errors in CU and NU (P > 0.1). As a result, 
 
 
the Δ9-THC-induced increase in inhibition errors was greater in NU than CU (P = 0.03). There was 
no significant effect of order of drug administration and no interaction between the effects of drug 
and order of administration on frequency of inhibition errors. 
 
fMRI results 
 
Verbal learning task  
Effects of Δ9-THC administration and lifetime cannabis exposure and their interaction  
 Factorial ANOVA revealed a main effect of lifetime cannabis exposure on activation during 
encoding, such that CU engaged the right caudate and parahippocampal gyrus more than NU 
(Figure S4). There was no significant main effect of Δ9-THC on brain activation during encoding. 
However, there was an interaction between Δ9-THC administration and lifetime cannabis exposure 
(Table S1). Under the placebo condition, encoding of word pairs was associated with activation in 
the right superior temporal gyrus in NU individuals (control group), whereas this region was 
deactivated in NU under the Δ9-THC condition, and in CU under both the Δ9-THC and placebo 
conditions (Figure 2A). Moreover, while NU individuals under the placebo condition deactivated 
the parahippocampal gyrus bilaterally, the left thalamus, and the right posterior cingulate, both NU 
under the Δ9-THC condition and CU under the placebo condition activated these areas. In addition, 
under the Δ9-THC condition, there was only weak left parahippocampal and thalamic activation in 
CU, and deactivation in the right parahippocampal gyrus and posterior cingulate, similar to NU 
under placebo (Figure 2B and 2C). Under the placebo condition NU activated the right inferior 
parietal lobule and precuneus, while both NU under the Δ9-THC condition and CU under the 
placebo condition deactivated this area. Intriguingly, once again CU under the Δ9-THC condition 
activated the right inferior parietal lobule and precuneus, showing a pattern of activation similar to 
NU under placebo (Figure 2D).  
 
 
 Factorial ANOVA during recall failed to show significant interaction between lifetime 
cannabis exposure and Δ9-THC administration (Supplementary results).       
 
Association between psychopathological measures, behavioral performance, and brain activation 
during verbal learning  
 Due to the established left-lateralized pattern of parahippocampal activation during encoding 
of verbal stimuli (Chua et al., 2007; Powell et al., 2005; Rosazza et al., 2009) and evidence here that 
the effect of Δ9-THC in this brain area differs between CU and NU, a correlation analysis was 
conducted to examine the relationship between brain activity in the left parahippocampal gyrus and 
behavioral measures that were also different between CU and NU, in particular AUC PANSS total 
score and improvement in recall score across repeated blocks (learning). In the NU group, the Δ9-
THC-induced change in left parahippocampal activation (Δ9-THC minus placebo) positively 
correlated with the severity of psychotic symptoms induced by Δ9-THC (rS: 0.61; P = 0.036; Figure 
3A) as well as with its effects on learning (Δ9-THC minus placebo; r: 0.63; P = 0.028; Figure 3B). 
These correlations were not observed in the CU group. Further, post-hoc testing indicated that the 
relationship between the effect of Δ9-THC on left parahippocampal gyrus engagement was specific 
to psychotic-like symptoms under its influence, as such a relationship did not exist between the 
engagement of the left parahippocampal gyrus induced by Δ9-THC and its effect on the severity of 
intoxication, sedation, and anxiety symptoms.    
  
Response inhibition (Go/No-Go) task  
Effects of Δ9-THC administration and lifetime cannabis exposure and their interaction  
 Factorial ANOVA revealed a main effect of lifetime cannabis exposure on brain function 
during inhibitory control processing, such that CU engaged the right postcentral gyrus extending to 
the inferior parietal lobule and superior temporal gyrus more than NU (Figure S6A). CU also 
showed a lower activation in the left middle and superior temporal gyri compared to NU (Figure 
 
 
S6B). Moreover, there was a main effect of Δ9-THC on brain activation, with greater right anterior 
cingulate (Figure S7A) and lesser left insula activation (Figure S7B) under Δ9-THC compared to 
placebo. There was an interaction between Δ9-THC administration and lifetime cannabis exposure 
(Figure 4) such that, while under the placebo condition inhibitory control processing was associated 
with an activation in the left inferior parietal lobule in NU individuals (control group), this brain 
area was deactivated in all the other groups (NU under the Δ9-THC condition; CU under the Δ9-
THC and the placebo conditions; Figure 4A). Moreover, while NU individuals under the placebo 
condition deactivated the right middle frontal gyrus, both NU under the Δ9-THC condition and CU 
under the placebo condition activated these areas. In contrast, CU under the Δ9-THC condition 
deactivated the right middle frontal gyrus, similarly to NU under placebo (Figure 4B). 
      
Association between psychopathological measures, behavioral performance, and brain activation 
during response inhibition 
 Due to the primary and selective involvement of left inferior parietal lobule during response 
inhibition control (Corbetta and Shulman, 2002; Kimberg et al., 2000; Sohn et al., 2000), and 
evidence from this study that the effect of Δ9-THC in this brain area differs between CU and NU, a 
correlation analysis was conducted to examine the relationship between patterns of brain activity in 
the left inferior parietal lobule and the behavioral measures which also appeared to differ in the two 
groups. Change in the left inferior parietal lobule activation induced by Δ9-THC (Δ9-THC minus 
placebo) negatively correlated with the severity of psychotic symptoms (rS: -0.61; P = 0.036; 
Figure 5A) and the frequency of inhibition errors (Δ9-THC minus placebo; rS: -0.61; P = 0.034; 
Figure 5B) induced by Δ9-THC in NU. Such correlations were not present in CU. Further, post-hoc 
testing indicated that the relationship between the effect of Δ9-THC on left inferior parietal lobule 
engagement was specific to psychotic-like symptoms under its influence, as such a relationship did 
not exist between the attenuation of left inferior parietal lobule engagement by Δ9-THC and its 
effect on the severity of intoxication, sedation, and anxiety symptoms.   
 
 
 
DISCUSSION 
 
 To our knowledge, this is the first report of the effects of previous cannabis exposure on the 
acute effects of Δ9-THC on the fMRI BOLD signal acquired during cognitive processing in man. 
Overall, results suggest that modest previous cannabis exposure is associated with disrupted brain 
activity and related cognitive impairments, but less pronounced responses to the psychotomimetic 
and neurocognitive effects of acute ∆9-THC administration.  
 Independent of the acute effects of ∆9-THC, CU displayed slower learning and greater 
engagement of the right caudate and parahippocampal gyrus (rPHG) than NU, suggesting that there 
were residual behavioural and neurophysiological effects of previous cannabis exposure. Similarly, 
compared to NU, during the response inhibition task (independent of ∆9-THC), CU made more 
inhibition errors and showed greater activation in the right inferior parietal lobule (rtIPL), superior 
temporal (rtSTG) and postcentral gyrus, and lower activation in the left middle and superior 
temporal gyri (ltMTG, ltSTG). Greater activation in task-related brain areas may represent a 
neurophysiological attempt to maintain compromised cognitive processing. Overall, these findings 
complement the existing larger body of research suggesting an association between cannabis use 
and verbal memory (Grant et al., 2003) as well as inhibitory control (Ganzer et al., 2016), and are in 
line with the evidence that deficits in memory, attention, and inhibition associated with cannabis 
use may persist after an adequate period of abstinence (Meier et al., 2012; Ganzer et al., 2016). 
Also, results from this study extend previous preclinical evidence (Kolb et al., 2006) as well as 
human studies (Gilman et al., 2014) suggesting that neurophysiological alterations can occur even 
after modest cannabis exposure. 
 The main aim of this study was to test the hypothesis that previous modest cannabis 
exposure modulated the behavioral and neurophysiological responses to acute administration of ∆9-
THC. Compared to NU, abstinent CU showed a blunted response to the psychotomimetic effects of 
 
 
acute ∆9-THC administration, consistent with previous research indicating a less marked effect of 
∆9-THC in frequent cannabis users relative to healthy controls (D'Souza et al., 2008b). Our 
neuroimaging findings extend these behavioral findings (D'Souza et al., 2008b) and complement 
previous electrophysiological evidence (Cortes-Briones et al., 2015; D'Souza et al., 2012) by 
indicating that the blunted behavioral response observed in CU under the effects of ∆9-THC is also 
associated with a less marked neurophysiological disruption. In particular, under the influence of 
∆9-THC, the pattern of brain activity observed in CU was similar to that adopted by NU under 
placebo. In healthy subjects, the rSTG, rIPL, and right precuneus are activated during the verbal 
learning task, reflecting the engagement of semantic and syntactic processing, deductive reasoning, 
and attentive control (Binder and Desai, 2011; Buchsbaum et al., 2011; Ciaramelli et al., 2008; 
Gaillard et al., 2011; Staresina and Davachi, 2006). However, NU in the presence of ∆9-THC and 
CU in the presence of placebo deactivated these areas, instead engaging the posterior cingulate 
gyrus and PHG, especially on the left side, consistent with previous evidence (Nestor et al., 2008). 
Hypoactivity in the temporal cortex and hyperactivity in the parahippocampus have been previously 
reported as a shift in brain activity identifying functional deficits and compensatory processes in 
CU (Nestor et al., 2008). Intriguingly, following ∆9-THC administration, CU activated rtIPL and 
right precuneus and only mildly engaged the ltPHG, partially reversing the deficits shown under 
placebo. During the response inhibition task, in order to perform the task NU under placebo 
activated the lIPL, a brain area selectively active at the time of a switch in discrimination tasks, 
reflecting the attentional adjustment needed to detect behaviorally relevant stimuli and elicit 
specific responses for a given task (Corbetta and Shulman, 2002; Kimberg et al., 2000; Sohn et al., 
2000). Under acute (∆9-THC challenge in NU) as well as residual (CU under placebo) effect of ∆9-
THC, this brain area was deactivated in both groups, perhaps reflecting poorer performance in NU 
under ∆9-THC and CU under placebo who instead activated the right middle frontal gyrus (rtMFG). 
These findings may reflect an acute and long-term deleterious effect of cannabis on the ability to 
detect salient and unexpected stimuli requiring behavior modification such as response inhibition. 
 
 
Instead, CU under ∆9-THC did not engage the rtMFG, partially reversing the deactivation in the 
ltIPL shown under placebo. In NU, the severity of psychotic symptoms and cognitive impairments 
following acute ∆9-THC administration was more pronounced than in CU, and was associated with 
a more marked disruption of the underlying brain activity. This pattern was absent in CU, who 
under the acute ∆9-THC condition showed a less prominent alteration in verbal learning and 
inhibitory control-related brain activity.  
 To account for these findings, several explanations can be advanced, which are not mutually 
exclusive. Preclinical evidence suggests that prolonged exposure to Δ9-THC leads to the 
development of tolerance for most of its pharmacological effects by a reduction in the number and 
signaling efficiency of cannabinoid receptors type 1 (CB1R) as a homeostatic response (Gonzalez et 
al., 2005). Therefore, the present findings seem to suggest that the development of tolerance to the 
effects of ∆9-THC could occur even after modest cannabis exposure and persist after an adequate 
period of abstinence (3 months). In contrast, other human evidence indicates a rapid reversal of 
CB1R downregulation following abstinence in chronic (Hirvonen et al., 2012) and dependent users 
(D'Souza et al., 2016). However, CB1R downregulation following protracted cannabis use is not 
homogeneous across the brain. Chronic cannabis use is not associated with CB1R downregulation 
in the basal ganglia, midbrain and cerebellum, whilst inducing a downregulation of CB1R in the 
hippocampus, which doesn’t reverse after abstinence (Hirvonen et al., 2012). Prolonged 
hippocampal CB1 downregulation could explain the persistence of tolerance to the effects of ∆9-
THC after abstinence and has also been proposed to contribute to the residual cognitive 
impairments associated with cannabis use (D'Souza, 2007). Future studies should therefore 
determine whether differing patterns of CB1R downregulation in different brain regions may 
underlie differing susceptibility to development of tolerance of the different behavioural and 
neurocognitive effects of cannabis.  
 It is also possible that underlying systematic differences in endocannabinoid signaling 
between the CU and NU groups linked to their distinct previous cannabis exposure history (Colizzi 
 
 
et al., 2015c; Taurisano et al., 2016) may have played a role in determining the precise direction of 
the pharmacological effect of ∆9-THC at the CB1 receptors, where it is known to have a partial 
agonist effect, thereby influencing systems-level effects indexed using fMRI. Preclinical evidence 
(Bilkei-Gorzo et al., 2017) is consistent with such a possibility and evidence that the effects of ∆9-
THC are influenced by CB1R expression level and signalling efficiency as well as ongoing 
endocannabinoid tone (Pertwee, 2008). Alternatively, we cannot exclude that CU under acute 
intoxication are no longer able to engage/ shift to additional brain areas as a compensatory strategy, 
suggesting a more pronounced cognitive dysfunction upon heavier cannabis use and/or while 
performing more demanding cognitive tasks. Preclinical evidence suggests that long-term exposure 
to ∆9-THC can alter the modulatory effect of endogenous and exogenous cannabinoids on synaptic 
transmission in brain areas relevant to cognitive processing (Colizzi et al., 2016b). However, the 
present study was not designed to examine these possibilities, which should be investigated in 
future studies.      
 The main strengths of the present study are the use of a control group of NU, an adequate 
period of abstinence, especially among CU confirmed with negative urine drug screen, and the 
fMRI design which allowed investigation of the neurophysiological underpinnings of cognitive 
impairments observed following both acute and non-acute cannabis exposure. On the other hand, as 
the CU individuals in this study were not heavy cannabis users, these results may not reflect what 
happens following abstinence in those with heavier patterns of use. Also, cumulative lifetime 
cannabis exposure was not measured using specific exposure constructs which could have offered a 
more reliable retrospective measure (Rabin et al., 2013). Moreover, as cannabis and tobacco are 
commonly smoked together, possible synergistic effects of the two substances deserve further 
investigation. However, given the modest cannabis use as well as the absence of heavy tobacco 
smokers in the study sample, this is unlikely to have systematically affected the results. As we 
studied only male participants in order to have a more homogenous sample, this limits 
generalizability to female cannabis users, which should be addressed in future investigations. The 
 
 
small sample size and the use of a 1.5T MR scanner and a relatively large voxel size represent 
limitations to be considered.  
Further investigation of the neurochemical explanations for the present findings and implications 
for mechanisms underlying the association between cannabis use and psychosis is warranted.  
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Figure 1. Acute effect of Δ9-THC in cannabis users and non-users 
∆9-THC, (−)-trans-Δ9-tetrahydrocannabinol; PANSS, Positive and Negative Syndrome 
Scale; h, hour; Dashed line, Placebo; Solid line, ∆9-THC; Circle marker, Non-users; 
Diamond marker, Cannabis-users  
Figure 2A. Interaction between Δ9-THC administration and lifetime 
cannabis exposure on brain function during verbal learning 
encoding 
A 
Cluster size: 39; x: 47, y: -59, z: 31; P =0.004   
‘Encoding’ condition contrasted with ‘baseline’ condition; ∆9-THC, (−)-trans-Δ9-
tetrahydrocannabinol; PLB, Placebo; CU, Cannabis users; NU, Non-users; Y-axis displays SSQ 
statistic; the cluster size refers to the specific brain area and is part of a larger cluster 
encompassing different brain areas (size: 56) 
Figure 2B. Interaction between Δ9-THC administration and lifetime 
cannabis exposure on brain function during verbal learning 
encoding 
B 
Cluster size: 5; x: -14, y: -33, z: 4; P = 0.001 
 
‘Encoding’ condition contrasted with ‘baseline’ condition; ∆9-THC, (−)-trans-Δ9-
tetrahydrocannabinol; PLB, Placebo; CU, Cannabis users; NU, Non-users; Y-axis displays SSQ 
statistic; the cluster size refers to the specific brain area and is part of a larger cluster 
encompassing different brain areas (size: 81) 
 
Figure 2C. Interaction between Δ9-THC administration and lifetime 
cannabis exposure on brain function during verbal learning 
encoding 
C 
Cluster size: 9; x: 7, y: -44, z: 9; P = 0.001 
‘Encoding’ condition contrasted with ‘baseline’ condition; ∆9-THC, (−)-trans-Δ9-
tetrahydrocannabinol; PLB, Placebo; CU, Cannabis users; NU, Non-users; Y-axis displays SSQ 
statistic ; the cluster size refers to the specific brain area and is part of a larger cluster 
encompassing different brain areas (size: 81) 
 
Figure 2D. Interaction between Δ9-THC administration and lifetime 
cannabis exposure on brain function during verbal learning 
encoding 
D 
Cluster size: 17; x: 40, y: -59, z: 37; P =0.004 
‘Encoding’ condition contrasted with ‘baseline’ condition; ∆9-THC, (−)-trans-Δ9-
tetrahydrocannabinol; PLB, Placebo; CU, Cannabis users; NU, Non-users; Y-axis displays SSQ 
statistic; the cluster size refers to the specific brain area and is part of a larger cluster 
encompassing different brain areas (size: 56) 
  
Figure	3.	Association	between	psychopathology,	verbal	learning,	and	
left	parahippocampal gyrus	and	thalamus	activation	after	Δ9-THC	
administration	in	Non-users
A B
∆9-THC,	(−)-trans-Δ9-tetrahydrocannabinol
(rS:	0.61;	P	=	0.036) (r:	0.63;	P	=	0.028)
Figure 4. Interaction between Δ9-THC administration and lifetime 
cannabis exposure on brain function during inhibition control processing 
Cluster size: 28; x: -36, y: -41, z: 48; P = 0.002 
 
Cluster size: 20; x: 29, y: -11, z: 48; P = 0.004 
A 
B 
‘No-Go’ condition (‘No-Go’ contrasted with ‘Go’) minus ‘Oddball’ condition (‘Oddball’ 
contrasted with ‘Go’); ∆9-THC, (−)-trans-Δ9-tetrahydrocannabinol; PLB, Placebo; CU, 
Cannabis users; NU, Non-users; Y-axis displays SSQ statistic  
Figure	5.	Association	between	psychopathology,	inhibitory	control	
processing,	and	left	inferior	parietal	lobule	activation	after	Δ9-THC	
administration	in	Non-users
(rS:	- 0.61;	P	=	0.036) (rS:	- 0.61;	P	=	0.034)A B
∆9-THC,	(−)-trans-Δ9-tetrahydrocannabinol
